Valiant Laboratories Limited
ESTD. 1980

August 10, 2026

To,
Listing/Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

BSE Scrip Code: 543998

To,
Listing/Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G-Block, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: VALIANTLAB

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on August 10, 2026
Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

This is to inform you that the Board of Directors of Valiant Laboratories Limited ('the Company') at its meeting held today i.e. on **Monday, August 10, 2026**, has *inter alia* considered and approved the following**:**

1. **Re-appointment of Managing Director**

   Approved the re-appointment of Mr. Santosh Vora (DIN: 07633923) as the Managing Director of the Company, based on the recommendation of the Nomination and Remuneration Committee, for a further period of five (5) years with effect from February 06, 2027, and the remuneration payable to him during the said tenure, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting and such other approvals as may be necessary.

2. **Re-appointment of Independent Director**

   Approved the re-appointment of Mrs. Sonal Vira (DIN: 09505883) as an Independent Director of the Company, based on the recommendation of the Nomination and Remuneration Committee for a second term of five (5) consecutive years with effect from February 16, 2027, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting, and such other approvals as may be necessary.

   Further, Mrs. Sonal Vira has confirmed that she meets the criteria of independence as prescribed under the provisions of the Companies Act, 2013 and the Rules made thereunder, as well as the Listing Regulations.

3. **Continuation of directorship of Non-Executive Non-Independent Director**

   Approved and recommended the continuation of directorship of Mr. Shantilal Vora (DIN: 07633852), as a Non-Executive Non-Independent Director of the Company upon his attaining the age of 75 years, with effect from November 05, 2027, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting, in terms of Regulation 17(1A) of the Listing Regulations.

Further, Mr. Santosh Vora, Mrs. Sonal Vira and Mr. Shantilal Vora are not debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority.

4. **Shifting of Registered Office of the Company**

Shifting of the Registered Office of the Company from **104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080** to **Plot No. L-13, L-28, L-28(Pt), L-29 & L-30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506**, resulting in a change in jurisdiction from the Registrar of Companies, Mumbai-I to the Registrar of Companies, Mumbai-II (Navi Mumbai), subject to the approval of the members of the Company by way of a Special Resolution, the confirmation of the Regional Director, Western Region, Ministry of Corporate Affairs, and such other approvals as may be required.

5. **Opening of a new Corporate Office of the Company**

Opening of a new Corporate Office of the Company at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai – 400083, from where the administrative, management, finance, secretarial and other corporate functions of the Company shall be carried out.

6. **Additional investment in Valiant Advanced Sciences Private Limited ("VASPL") up to an amount not exceeding Rs. 60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares**

Approval for making further investment in Valiant Advanced Sciences Private Limited ("VASPL"), a wholly owned subsidiary of the Company, up to an aggregate amount not exceeding ₹60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares, in one or more tranches, subject to applicable laws and approvals, if any.

The details as required under Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI LODR Master Circular') are enclosed herewith as "**Annexure-A" (re-appointment of Directors and continuation of directorship) and "Annexure-B" (investment in VASPL).**

The Board Meeting commenced at 04:30 p.m. and concluded at 06:00 p.m.

This intimation is also being uploaded on the Company's website at www.valiantlabs.in.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For **Valiant Laboratories Limited**

AKSHAY DNYANESHWAR GANGURDE
Digitally signed by AKSHAY DNYANESHWAR GANGURDE
Date: 2026.08.10 20:10:04 +05'30'

Akshay Gangurde
Company Secretary & Compliance Officer
Encl: As above

Annexure – A

Details of re-appointment of Directors and continuation of directorship

Sr. No.	Particulars	Disclosure		
1	**Name of Director**	**Mrs. Sonal Vira**	**Mr. Santosh Vora**	**Mr. Shantilal Vora**
2	**Reason for change viz. appointment, reappointment, ~~resignation, removal, death or otherwise~~**	Re-appointment of Mrs. Sonal Vira (DIN: 09505883) as an Independent Director of the Company for a second term.	Re-appointment of Mr. Santosh Vora (DIN: 07633923) as a Managing Director of the Company.	Continuation of directorship of Mr. Shantilal Vora (DIN: 07633852), as Non-Executive Non-Independent Director of the Company upon attaining the age of 75 years.
3	**Date and term of Appointment /Re-Appointment**	**Date of re-appointment –** Effective from February 16, 2027, subject to the approval of the members by way of a Special Resolution at the ensuing AGM. **Term of re-appointment –** Five (5) consecutive years, NOT liable to retire by rotation.	**Date of re-appointment –** Effective from February 06, 2027, subject to the approval of the members at the ensuing AGM. **Term of re-appointment –** Five (5) consecutive years, NOT liable to retire by rotation.	Date of continuation – Effective from November 05, 2027, subject to the approval of the members by way of a Special Resolution at the ensuing AGM, in terms of Regulation 17(1A) of the Listing Regulations. **Term –** Continuation as a Non-Executive Non-Independent Director, liable to retire by rotation
4	**Brief Profile**	Mrs. Sonal Vira is a Commerce graduate from the University of Mumbai and a Chartered Accountant from the ICAI. She has over 15 years of experience in corporate banking, having handled clients across the entire spectrum of the market, from large domestic conglomerates to multinational corporations and mid-market companies. Her skills include a sound understanding of	Mr. Santosh Vora holds a bachelor's degree in commerce with specialization in Financial Markets from University of Mumbai and has also completed the Post Graduate Programme in Management for Family Business from The Indian School of Business (ISB), Hyderabad. He has over 8 years of experience in the chemical and pharmaceutical	Mr. Shantilal Vora has over 45 years of experience in the chemical and pharmaceutical industry. He specialises in developing new markets and customers, both for the Company's existing products and for its new business segments and has vast experience in handling the sales and marketing of bulk drugs. His key areas of

		financial analysis and credit evaluation techniques, together with hands-on experience in relationship management, credit appraisal, product development and promotions.	industry. He looks after the overall management of the Company and plays a key role in its various growth initiatives. He specialises in the development of new products and the introduction of new chemistries in the Company, and also oversees process optimisation. In addition to his technical acumen, he possesses a sound understanding of the financial and commercial aspects of the pharmaceutical and chemical industry.	expertise include the commercial functions of the Company, encompassing purchases, domestic sales and exports.
5	**Disclosure of relationships between directors (in case of appointment of a director)**	Mrs. Sonal Vira is not related to any Director of the Company.	Mr. Santosh Vora is the son of Mr. Shantilal Vora, Non-Executive Non-Independent Director and Promoter of the Company.	Mr. Shantilal Vora is the father of Mr. Santosh Vora, Managing Director and Promoter of the Company.

Valiant Laboratories Limited
ESTD. 1980

<u>**Annexure-B**</u>

Investment in Valiant Advanced Sciences Private Limited

Sr.No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover, etc.	Valiant Advanced Sciences Private Limited ("VASPL") is engaged in the manufacture of speciality chemicals, including acetic anhydride, ketene and diketene derivatives. <u>As on March 31, 2026:</u> Net worth: ₹15,618.41 Lakh Turnover (FY 2025-26): ₹4,164.86 Lakh
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	VASPL, being a wholly owned subsidiary of the Company, is a related party of the Company. The proposed investment would accordingly fall within related party transaction(s) and the same is at arms' length basis. Save to the extent of the shareholding of the Company in VASPL, none of the promoter / promoter group / group companies of the Company has any interest in VASPL.
3	Industry to which the entity being acquired belongs Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Speciality Chemicals. VASPL is engaged in the manufacture of speciality chemicals, including acetic anhydride, ketene and diketene derivatives. **Object:** The investment is proposed to be made to meet the working capital requirements and general corporate purposes of VASPL, and to strengthen its capital base to support its ongoing business operations. Currently, Valiant Laboratories Limited is holding 100% share capital of VASPL and with the current investment, Valiant Laboratories Limited's shareholding percentage in VASPL will remain unchanged. VASPL's business being in the speciality chemicals sector, the proposed investment is not outside the main line of business of the Company.
4	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approval is required for the proposed investment, other than the corporate approvals required under the applicable provisions of the Companies Act, 2013.
5	Indicative time period for completion of the acquisition	The investment is proposed to be made in one or more tranches, as may be decided by the Board of Directors depending upon the fund requirements of VASPL, and is expected to be

		completed within a period of 12 months from the date of this approval.
6	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration.
7	Cost of acquisition or the price at which the shares are acquired	Up to an aggregate amount not exceeding ₹60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares.
8	Percentage of shareholding/ control acquired and/or number of shares acquired	There will be no change in the percentage of the equity shareholding of the Company in VASPL, which shall continue to remain a wholly owned subsidiary of the Company.
9	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	VASPL was incorporated under the Companies Act, 2013 on July 08, 2022 as a Wholly Owned Subsidiary of the Company. VASPL is engaged in the manufacture of speciality chemicals, including acetic anhydride, ketene and diketene derivatives. Its operations are located in India. The turnover of VASPL for the last three financial years is given below: Year — Turnover (₹ in Lakh) 2025-26 — 4,164.86 2024-25 — 2.02 2023-24 — 0.48